...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >A gender analysis of the study of pharmacotherapy of psychotic depression (STOP-PD): Gender and age as predictors of response and treatment-associated changes in body mass index and metabolic measures
【24h】

A gender analysis of the study of pharmacotherapy of psychotic depression (STOP-PD): Gender and age as predictors of response and treatment-associated changes in body mass index and metabolic measures

机译：精神病性抑郁症（STOP-PD）药物治疗研究的性别分析：性别和年龄是反应的预测因子，并且与体重指数和代谢指标相关的治疗相关变化

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Gender differences exist in psychiatric disorders; however, gender has not been well studied in psychotic depression. This analysis of the largest clinical trial in psychotic depression examined the effects of age and gender on clinical characteristics and predictors of treatment outcome and treatment-associated changes in body mass index (BMI) and metabolic measures. Method: Secondary analyses were performed on data from 259 subjects with major depressive disorder with psychotic features (DSM-IV-TR) aged 18-93 years in the double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression (Study of Pharmacotherapy of Psychotic Depression). Sociodemographic factors, clinical characteristics, treatment outcome, and treatment-associated changes in BMI and metabolic measures were analyzed by gender and age. Subjects were enrolled from December 2002 to June 2007. Results: Female gender was associated with divorced (Χ2 1 = 5.3, P = .03) or widowed (Χ 2 1 = 8.1, P ≤ .01) marital status. Comorbid anxiety disorders were more common in women than in men (Χ2 1 = 4.9, P = .03). Hallucinations (Χ2 1 = 7.8, P = .005) and delusions with disorganization (t257 = -2.10, P = .04) were significantly associated with female gender, as were higher cholesterol measures (Χ2 1 = 7.15, P = .008). There were no significant interactions between treatment and gender in terms of change in BMI. Gender was not associated with treatment response. Discussion: This study is the first analysis of gender and age as predictors of treatment outcome and treatment-associated changes in BMI and metabolic adverse effects in psychotic depression. Gender differences exist in patients with psychotic depression, most notably with regard to the presence of hallucinations. Female gender was associated with metabolic measures. Future studies with larger sample sizes may detect small gender differences in treatment outcome and treatment-associated changes in BMI and metabolic measures in psychotic depression.
机译：背景：精神疾病存在性别差异;然而，对精神病性抑郁症的性别研究尚未深入。这项对最大的精神病性抑郁症临床试验的分析分析了年龄和性别对临床特征的影响以及治疗结局，与体重指数（BMI）和代谢相关的治疗相关变化的预测指标。方法：在奥氮平加舍曲林与奥氮平加安慰剂治疗精神病性抑郁症的双盲随机对照试验中，对来自259名年龄在18-93岁的具有精神病特征的重度抑郁症患者（DSM-IV-TR）的数据进行了二级分析。精神病性抑郁症的药物治疗研究）。通过性别和年龄分析社会人口统计学因素，临床特征，治疗结果以及与治疗相关的BMI变化和代谢指标。研究对象从2002年12月至2007年6月入组。结果：女性性别与离婚（Χ21 = 5.3，P = .03）或寡居（Χ21 = 8.1，P≤.01）婚姻状况相关。女性共病性焦虑症比男性更常见（Χ21 = 4.9，P = .03）。幻觉（Χ21 = 7.8，P = .005）和妄想混乱（t257 = -2.10，P = .04）与女性性别显着相关，胆固醇水平较高（Χ21 = 7.15，P = .008） 。就BMI的变化而言，治疗与性别之间没有显着的相互作用。性别与治疗反应无​​关。讨论：这项研究是对性别和年龄进行的首次分析，可作为治疗结果和与治疗相关的BMI变化以及精神病性抑郁症的代谢不良反应的预测指标。精神病性抑郁症患者存在性别差异，特别是在出现幻觉方面。女性性别与代谢措施有关。将来有更大样本量的研究可能会发现治疗结果的性别差异较小，以及与精神病性抑郁症的BMI和代谢指标相关的治疗相关变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号